# Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

Study · id `cardio:ct-nct06946589` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06946589](<https://clinicaltrials.gov/study/NCT06946589>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06946589

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06946589. Randomized; double masking; primary purpose treatment. Start 2025-08-01 (anticipated); primary completion 2026-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06946589, source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)
- Planned start: 2025-08-01 (anticipated) (ClinicalTrials.gov record NCT06946589, source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)
- Primary completion: 2026-08-01 (anticipated) (ClinicalTrials.gov record NCT06946589, source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)
- Completion: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT06946589, source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06946589, source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06946589-2025-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section
- Condition: Cardiac Ischemia
- Condition: Cesarian Section
- Intervention (Drug): Carbetocin
- Lead sponsor: Jordan Leitch
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 8b97ad956274849d56c7e71aa77b2f3f383f6063e95297067adb995921dc95a7
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
